These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30629793)

  • 1. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.
    Stefanou MI; Richter H; Härtig F; Wang Y; Örgel A; Bender B; Mengel A; Ziemann U; Poli S
    Eur J Neurol; 2019 Jun; 26(6):903-e64. PubMed ID: 30629793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare cause of acute coronary syndromes in young adults - myeloproliferative neoplasms: A case series.
    Cengiz B; Aytekin V; Bildirici U; Sahin ST; Yurdakul S; Aytekin S; Kucukkaya R
    Rev Port Cardiol (Engl Ed); 2019 Sep; 38(9):613-617. PubMed ID: 31784298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
    Haybar H; Khodadi E; Shahjahani M; Saki N
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.
    Enblom A; Lindskog E; Hasselbalch H; Hersby D; Bak M; Tetu J; Girodon F; Andréasson B
    Eur J Intern Med; 2015 Jun; 26(5):344-7. PubMed ID: 25863408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diagnostics of myeloproliferative neoplasms.
    Langabeer SE; Andrikovics H; Asp J; Bellosillo B; Carillo S; Haslam K; Kjaer L; Lippert E; Mansier O; Oppliger Leibundgut E; Percy MJ; Porret N; Palmqvist L; Schwarz J; McMullin MF; Schnittger S; Pallisgaard N; Hermouet S;
    Eur J Haematol; 2015 Oct; 95(4):270-9. PubMed ID: 25951317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].
    Xia L; Ding KY; Cai XY; Zhu WB; Liu X; Yang HZ; Wan X; Wu LL; Zeng QS; Wu JS
    Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):590-3. PubMed ID: 21122317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.